Cerebras Targets $115–$125 Per Share in US IPO, Betting Its Wafer-Scale AI Chips Can Outpace Nvidia

Cerebras Targets $115–$125 Per Share in US IPO, Betting Its Wafer-Scale AI Chips Can Outpace Nvidia

Cerebras Systems, a Silicon Valley AI chipmaker, is reportedly targeting a share price between $115 and $125 for its upcoming US initial public offering, according to Reuters. What makes the company unusual — and its valuation conversation-worthy — is its hardware approach: rather than building conventional processors, Cerebras manufactures chips the size of an entire silicon wafer, packing in significantly more transistors than standard GPUs. The result is a processor purpose-built to train large AI models faster and at greater scale.

The proposed price range would place Cerebras among the most closely watched tech debuts in years, arriving at a moment when investor appetite for AI-adjacent companies remains strong but not uncritical. Some analysts have noted the valuation reflects the broader premium the market is assigning to AI infrastructure plays — a category that has attracted both serious capital and pointed skepticism about whether current pricing can be sustained. Cerebras's ability to compete with entrenched players like Nvidia, which dominates the AI chip market, remains an open question that the IPO prospectus will need to address directly.

The roadshow will essentially be a public stress test of whether AI infrastructure optimism has a ceiling.

Gobble's Take: The IPO pricing tells you where institutional money thinks AI hardware is headed — but the post-listing quarter will be the real data point.

Source: Reuters

Slide Insurance Holdings Surges — Analysts Are Now Asking Whether the Valuation Has Run Ahead of the Risk

Slide Insurance Holdings (SLDE), a property insurer focused on hurricane-exposed states largely vacated by major carriers, has seen its share price climb enough to draw formal valuation scrutiny. According to Yahoo Finance, analysts are now assessing whether the recent momentum reflects genuine business strength or sentiment that has moved faster than fundamentals.

The company operates in one of the harder corners of US insurance: coastal and catastrophe-prone markets where larger incumbents have reduced exposure or exited entirely. That positioning has allowed Slide to grow its book of business, but it also means its financial results carry outsized sensitivity to weather events and reinsurance costs — factors that don't show up cleanly in short-term price momentum. Investors weighing the stock after its run-up will need to look past recent share price performance and examine loss ratios, reinsurance treaties, and geographic concentration before drawing conclusions.

In catastrophe-exposed insurance, a quiet earnings quarter and a busy hurricane season can look identical on a chart — until they don't.

Gobble's Take: Share price momentum in a climate-risk insurer is worth examining closely — the next major storm season is never far off the calendar.

Source: Yahoo Finance

Novacyt Reports Q4 Growth — Stock Falls Anyway, Illustrating Why Expectations Matter More Than Headlines

Novacyt, a diagnostics company whose revenue profile was reshaped by pandemic-era testing demand, reported growth in its Q4 2025 results — and its stock declined in response, according to an earnings call transcript reviewed by Investing.com Nigeria. The divergence is a familiar pattern in the biotech and diagnostics sector, where reported figures are measured not against prior performance but against forward expectations set by analysts.

The most likely explanation, based on the available reporting, is that Novacyt's results or forward guidance came in below what the market had priced in — meaning investors who had already bid the stock up ahead of earnings found the actual numbers insufficient to justify current levels. For diagnostics companies specifically, this dynamic is sharpened by the post-pandemic hangover: firms that saw outsized revenue from COVID testing are now being held to demanding organic growth standards that exclude that windfall. Whether Novacyt's underlying business, stripped of those tailwinds, is growing fast enough to satisfy analysts is the central question the earnings call raised but may not have fully answered.

A stock that falls on a positive earnings report is the market's way of saying the bar was set somewhere else entirely.

Gobble's Take: Before an earnings release, the number that matters most is the consensus estimate — not the one the company reports.

Source: Investing.com Nigeria

In Case You Missed It

Yesterday's top stories:

• 36,000 People on Reddit Just Pledged $22 Million to Buy Spirit Airlines' Corpse
• TransUnion Shares Slide — Analysts Ask Whether the Selloff Has Gone Too Far